Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 3/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28918776 | 1.00 | BTK (0.49) | BTKJAK3F10MAP4K4FFAR4 | |
| SCHEMBL28605703 | 0.86 | SYK (0.51) | BTKJAK3F10MAP4K4CA1 | |
| SCHEMBL28605705 | 0.86 | SYK (0.51) | BTKJAK3F10MAP4K4CA1 | |
| SCHEMBL23484542 | 0.85 | MAP4K4 (0.49) | BTKJAK3F10MAP4K4CA1 | |
| SCHEMBL31318667 | 0.83 | SUV39H2 (0.51) | DRD2 | |
| SCHEMBL28595542 | 0.80 | SYK (0.50) | DRD2DRD3SYK | |
| SCHEMBL28595540 | 0.80 | SYK (0.50) | DRD2DRD3SYK | |
| SCHEMBL27128583 | 0.79 | BTK (0.51) | BTKJAK3F10MAP4K4CA1 | |
| SCHEMBL4436879 | 0.79 | MAP4K4 (0.52) | BTKJAK3F10MAP4K4CA1 | |
| SCHEMBL6484872 | 0.78 | BTK (0.49) | BTKJAK3F10MAP4K4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2024-10-08 | — | — | US | disclosed |
| CN-113164461-A | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110287-B2 | Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | BTK 2097/4885JAK3 4671/4885F10 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.